Business Context and Reporting Period
Company: Redhill Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: January 14, 2014
Context: The Company announced a definitive agreement for a private placement transaction to raise capital for working capital, research and development (specifically Phase III studies for RHB-104 and RHB-105), and potential acquisitions.
Key Financial Metrics
The filing details a specific financing event rather than a full period financial report. Key metrics related to the transaction include:
- Financing Amount: Approximately $11.7 million in gross proceeds.
- Equity Issuance: 10,458,740 ordinary shares.
- Share Price: 3.9 NIS per ordinary share.
- Warrants Issued: Warrants to purchase 4,183,496 ordinary shares.
- Warrant Terms: Three-year term; exercise price of 4.9 NIS per share (linked to NIS-US dollar exchange rate).
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for revenue, profit, operating cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the execution of a definitive agreement for a private placement. This represents a significant capital raise intended to fund clinical development and operations. The transaction is expected to close by the end of January 2014, subject to customary closing conditions.
Guidance, Outlook, and Risks
- Use of Proceeds: General working capital, R&D (Phase III studies for Crohn's disease and H. pylori infection), and potential acquisitions.
- Lock-up Provision: The Company undertook a six-month limitation from the execution date on issuing additional ordinary shares to new investors unless the effective price is at least NIS 3.455 per share. This does not apply to existing investors in this placement, employee option plans, or warrant exercises.
- Contingencies: Closing is subject to the satisfaction of customary conditions.
- Warrant Adjustments: Exercise price and share count are subject to adjustments for stock splits, dividends, or rights grants.
Investor Verification Checklist
- Confirm the closing of the $11.7 million private placement by the end of January 2014.
- Verify the final number of shares and warrants issued upon closing.
- Monitor the progress of Phase III clinical trials for RHB-104 and RHB-105 as the primary use of funds.
- Track compliance with the six-month pricing floor (NIS 3.455) for any future equity issuances to new investors.
- Review subsequent filings for updates on the NIS-US dollar exchange rate impact on warrant exercise prices.